These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 3108013)

  • 1. Lack of relationship between sodium valproate-induced adverse effects and the plasma concentration of its metabolite 2-propylpenten-4-oic acid.
    Paganini M; Zaccara G; Moroni F; Campostrini R; Bendoni L; Arnetoli G; Zappoli R
    Eur J Clin Pharmacol; 1987; 32(2):219-22. PubMed ID: 3108013
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Is 2-propyl-4-pentenoic acid, a hepatotoxic metabolite of valproate, responsible for valproate-induced hyperammonemia?
    Kondo T; Ishida M; Kaneko S; Hirano T; Otani K; Fukushima Y; Muranaka H; Koide N; Yokoyama M; Nakata S
    Epilepsia; 1992; 33(3):550-4. PubMed ID: 1350534
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Associations between risk factors for valproate hepatotoxicity and altered valproate metabolism.
    Kondo T; Kaneko S; Otani K; Ishida M; Hirano T; Fukushima Y; Muranaka H; Koide N; Yokoyama M
    Epilepsia; 1992; 33(1):172-7. PubMed ID: 1733753
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Distribution of valproic acid and its metabolites in various brain areas of dogs and rats after acute and prolonged treatment.
    Löscher W; Nau H
    J Pharmacol Exp Ther; 1983 Sep; 226(3):845-54. PubMed ID: 6411902
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Valproate metabolites in serum and urine during antiepileptic therapy in children with infantile spasms: abnormal metabolite pattern associated with reversible hepatotoxicity.
    Fisher E; Siemes H; Pund R; Wittfoht W; Nau H
    Epilepsia; 1992; 33(1):165-71. PubMed ID: 1733752
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of associated antiepileptic treatment on valproate-induced hyperammonemia.
    Zaccara G; Paganini M; Campostrini R; Moroni F; Valenza T; Messori A; Bartelli M; Arnetoli G; Zappoli R
    Ther Drug Monit; 1985; 7(2):185-90. PubMed ID: 3927530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Acute changes of blood ammonia may predict short-term adverse effects of valproic acid.
    Zaccara G; Campostrini R; Paganini M; Moroni F; Valenza T; Targioni G; Arnetoli G; Zappoli R; Baruzzi A
    Neurology; 1984 Nov; 34(11):1519-21. PubMed ID: 6436733
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetic aspects of drug effects in vitro: effects of serum protein binding on concentration and teratogenicity of valproic acid and 2-en-valproic acid in whole embryos in culture.
    Lewandowski C; Klug S; Nau H; Neubert D
    Arch Toxicol; 1986 Apr; 58(4):239-42. PubMed ID: 3087328
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Biotransformation and pharmacokinetics in the rhesus monkey of 2-n-propyl-4-pentenoic acid, a toxic metabolite of valproic acid.
    Rettenmeier AW; Gordon WP; Prickett KS; Levy RH; Baillie TA
    Drug Metab Dispos; 1986; 14(4):454-64. PubMed ID: 2873993
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the pharmacological and biochemical profiles of valproic acid (VPA) and its cerebral metabolite (2-en-VPA) after oral administration in mice.
    Keane PE; Simiand J; Morre M
    Methods Find Exp Clin Pharmacol; 1985 Feb; 7(2):83-6. PubMed ID: 2859407
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Simultaneous determination of valproic acid and 2-propyl-4-pentenoic acid for the prediction of clinical adverse effects in Chinese patients with epilepsy.
    Chen ZJ; Wang XD; Wang HS; Chen SD; Zhou LM; Li JL; Shu WY; Zhou JQ; Fang ZY; Zhang Y; Huang M
    Seizure; 2012 Mar; 21(2):110-7. PubMed ID: 22055352
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Chronic valproic acid therapy and incidence of increases in venous plasma ammonia.
    Haidukewych D; John G; Zielinski JJ; Rodin EA
    Ther Drug Monit; 1985; 7(3):290-4. PubMed ID: 3931312
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Valproate-induced hyperammonaemia in two epileptic identical twins.
    Campostrini R; Zaccara G; Rossi L; Paganini M; Dorigotti A; Zappoli R
    J Neurol; 1985; 232(3):167-8. PubMed ID: 3928828
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Valproic acid and active unsaturated metabolite (2-en): transfer to mouse liver following human therapeutic doses.
    Nau H; Loscher W
    Biopharm Drug Dispos; 1985; 6(1):1-8. PubMed ID: 3921077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hyperammonaemia and hepatotoxicity during chronic valproate therapy: enhancement by combination with other antiepileptic drugs.
    Ratnaike RN; Schapel GJ; Purdie G; Rischbieth RH; Hoffmann S
    Br J Clin Pharmacol; 1986 Jul; 22(1):100-3. PubMed ID: 3091053
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of valproic acid and metabolites in mouse plasma and brain following constant-rate application of the drug and its unsaturated metabolite with an osmotic delivery system.
    Nau H; Zierer R
    Biopharm Drug Dispos; 1982; 3(4):317-28. PubMed ID: 6819013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperamino-acidaemia and hyperammonaemia in epileptic children treated with valproic acid.
    Iinuma K; Hayasaka K; Narisawa K; Tada K; Hori K
    Eur J Pediatr; 1988 Dec; 148(3):267-9. PubMed ID: 3145882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Transfer of valproic acid and its main active unsaturated metabolite to the gestational tissue: correlation with neural tube defect formation in the mouse.
    Nau H
    Teratology; 1986 Feb; 33(1):21-7. PubMed ID: 3090732
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Blood ammonia level during valproic acid therapy.
    Kugoh T; Yamamoto M; Hosokawa K
    Jpn J Psychiatry Neurol; 1986 Dec; 40(4):663-8. PubMed ID: 3110472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of valproate and E-2-en-valproate on functional and morphological parameters of rat liver. II. Influence of phenobarbital comedication.
    Löscher W; Nau H; Wahnschaffe U; Hönack D; Rundfeldt C; Wittfoht W; Bojic U
    Epilepsy Res; 1993 Jun; 15(2):113-31. PubMed ID: 8370349
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.